TARS Stock — Tarsus Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$78.09

Market cap

$3,654.0M

Cash

$449.7M

Enterprise value

$3,277.1M

Balance sheet

Cash	$449.7M
Debt	$72.8M
Net cash	$376.9M
Enterprise value	$3,277.1M
Basic shares	43.3M shares
Fully diluted shares	51.5M shares
Fully diluted market cap	$4,020.7M
Cash per share	$10.39

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TARS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	lotilaner	Phase 2	Ocular Rosacea	—
Nov 12 - Dec 24	TP-05 (lotilaner) Low Dose	Phase 2	Lyme Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

XDEMVY

Approved · Active Modality: small molecule

Aliases TP-03, lotilaner ophthalmic solution 0.25%

Target GABA-Cl

Partnerships LianBio Ophthalmology Limited: exclusive commercial rights for TP-03 in Demodex blepharitis and MGD in the China Territory. Elanco: licensor of lotilaner-related IP in therapeutic fields of use

Indications

Demodex blepharitis (Approved)

Status note Approved product (lotilaner) for Demodex blepharitis; commercial revenues and China out-license revenue (collaboration revenue) reported in the filing.

TP-04

Phase 2 · Active Modality: small molecule

Target GABA-Cl

Partnerships Elanco: licensor of lotilaner-related IP in therapeutic fields of use

Indications

Ocular rosacea (Phase 2)
Papulopustular rosacea (Phase 2)

Catalysts

— None

Status note Investigational sterile aqueous gel formulation of lotilaner. Phase 2 trial for ocular rosacea (topline expected H1 2027); Phase 2a Galatea trial for papulopustular rosacea.

TP-05

Phase 2 · Active Modality: small molecule

Target GABA-Cl

Partnerships Elanco: licensor of lotilaner-related IP in therapeutic fields of use

Indications

Lyme disease prophylaxis (Phase 2)
Community malaria reduction (Phase 2)

Status note Investigational oral tablet formulation of lotilaner. Phase 2a Carpo trial initiated for prevention of Lyme disease in humans; Phase 2 trials initiated for community malaria reduction.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	lotilaner
Lead indication	Ocular Rosacea
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07443202	Phase 2	Enrolling by invitation	Sponsor	TARS	—	Ocular Rosacea	—
NCT07562087	Phase 2	Active, not recruiting	Sponsor	TARS	—	Lyme Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Tarsus Pharmaceuticals, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	3,357,059	+11,034	1.80%	2026-08-14
Frazier Life Sciences	728,644	no change	1.00%	2026-08-14
OrbiMed Advisors	35,581	+35,581	0.04%	2026-08-14
Ikarian Capital	31,166	no change	0.32%	2026-08-14
Braidwell LP	0	-265,715	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TARS — Tarsus Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders